Oncol Res Treat. 2019;42(3):87-94. doi: 10.1159/000495474. Epub 2019 Feb 27.
The treatment of oligometastatic disease is challenging and few data exist to guide treatment decisions. The objective of this study was to improve the data on the prevalence and treatment of patients with oligometastatic disease.
We conducted a prospective single-center analysis that included all consecutive patients discussed in multidisciplinary tumor boards (MDT) between February and July 2017. Patients with oligometastatic disease were identified and treatment strategies were evaluated.
1,673 patients were included in this study, 609 (36.4%) presented with metastatic disease, 151 (9%) had oligometastatic disease. Common metastatic sites were brain, liver, and lung. Lung cancer patients were the largest cohort (20.5%) among all patients with oligometastatic disease compared with other tumor entities. The majority of oligometastatic patients (68.9%) received local treatment with or without additional chemotherapy, 17.9% were recommended systemic therapy alone. MDT recommended watchful waiting for 4.6% of the patients.
Patients with oligometastatic disease represent a considerable proportion of all patients in MDT. In this study, 68.9% of patients with oligometastatic disease received regional treatment. This shows a possible treatment shift from palliative to potentially curative intent. These data may be used to design prospective clinical trials to optimize the treatment of oligometastatic disease.
寡转移疾病的治疗具有挑战性，目前几乎没有数据可用于指导治疗决策。本研究旨在增加寡转移疾病患者的患病率和治疗数据。
我们进行了一项前瞻性单中心分析，纳入了 2017 年 2 月至 7 月间多学科肿瘤委员会（MDT）讨论的所有连续患者。识别出寡转移疾病患者，并评估了治疗策略。
本研究共纳入 1673 例患者，其中 609 例（36.4%）为转移性疾病患者，151 例（9%）为寡转移疾病患者。常见的转移部位是脑、肝和肺。肺癌患者是所有寡转移疾病患者中最大的队列（20.5%），与其他肿瘤实体相比。大多数寡转移患者（68.9%）接受了局部治疗，联合或不联合化疗，17.9%仅接受了全身治疗。MDT 建议对 4.6%的患者进行观察等待。
寡转移疾病患者在 MDT 中的比例相当大。在这项研究中，68.9%的寡转移疾病患者接受了区域治疗。这表明治疗可能从姑息性转向潜在的治愈性。这些数据可用于设计前瞻性临床试验，以优化寡转移疾病的治疗。
